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XM02, the First Biosimilar G-CSF, is Safe and Effective in
Reducing the Duration of Severe Neutropenia and
Incidence of Febrile Neutropenia in Patients with Small Cell
or Non-small Cell Lung Cancer Receiving Platinum-Based
Chemotherapy
Ulrich Gatzemeier, MD,* Tudor Ciuleanu, MD,† Mircea Dediu, MD,‡ Elena Ganea-Motan, MD,§
Heinz Lubenau, PhD, and Auro Del Giglio, MD¶#
Background: Recombinant granulocyte colony-stimulating factors
such as Neupogen are used to treat chemotherapy-induced neutro-
penia. The aim of the study was to show that a new granulocyte
colony-stimulating factor, XM02, is as safe and effective as Neu-
pogen in the treatment of chemotherapy-induced neutropenia in
patients with small cell or non-small cell lung cancer.
Patients and methods: A total of 240 patients receiving platinum-
based chemotherapy were randomized in cycle 1 to treatment with
daily injections (subcutaneous 5 g/kg/d) of XM02 (n  160) or
Filgrastim Neupogen (n  80) for at least 5 days and a maximum of
14 days. In subsequent cycles, all patients received XM02.
Results: The mean duration of severe neutropenia was 0.5 and 0.3 days
in cycle 1 for XM02 and Filgrastim, respectively. In the analysis of
covariance for duration of severe neutropenia in cycle 1, the estimated
treatment difference “XM02 minus Filgrastim” was 0.157 days, with
95% confidence level (0.114 days, 0.428 days), which was included
in the prespecified equivalence range (1, 1). There was no statistically
significant difference of the end point incidence of febrile neutropenia
in cycle 1 between XM02 and Filgrastim (p  0.2347). The adverse
event profile was similar between XM02 and Filgrastim.
Conclusion: XM02 demonstrated similar efficacy and safety profile
as the reference medication Filgrastim in cycle 1. In conclusion,
treatment with XM02 is beneficial in ameliorating severe neutrope-
nia and febrile neutropenia in lung cancer patients receiving myelo-
suppressive chemotherapy. XM02 is safe and well tolerated in the
doses applied in this study.
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Cancer chemotherapy frequently leads to neutropenia,which affects more than one in three patients receiving
chemotherapy for cancer. Patients with severe neutropenia
(absolute neutrophil count (ANC) 0.5  109/L) are at high
risk to develop potentially life-threatening infections. Recom-
binant granulocyte colony-stimulating factors (G-CSFs) are
effective pharmaceutical substances and are successfully ap-
plied to treat chemotherapy-induced neutropenia.1
Natural human G-CSF is a glycoprotein composed of a
single polypeptide chain of 174 or 177 amino acids.2,3 The
bacterially synthesized nonglycosylated recombinant methionyl
form of human G-CSF (r-metHuG-CSF) has been approved
under the generic name Filgrastim and is marketed under the
trade name Neupogen (Amgen Inc., Thousand Oaks, CA).
BioGeneriX AG has clinically developed XM02, a
nonglycosylated r-metHuG-CSF expressed in Escherichia
coli for intravenous (i.v.) and subcutaneous (s.c.) administra-
tion in the treatment of chemotherapy-induced neutropenia as
biosimilar to the reference Filgrastim Neupogen. The manu-
facturing process was developed by Sicor Biotech.
The primary aim of the study was to show efficacy and
safety of XM02 compared with Filgrastim in the treatment of
chemotherapy-induced neutropenia in patients with lung cancer.
PATIENTS AND METHODS
Patients
Between December 2004 and December 2005, patients
with lung cancer requiring chemotherapy participated at 47
centers in 11 countries. The study was approved by local
institutional review boards and ethics committees. Male and
female patients18 years of age with small cell or non-small
cell lung cancer were eligible to participate if they signed and
dated written informed consent, were planned/eligible to
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receive a platinum-based myelosuppressive chemotherapy, were
chemotherapy-naive or had received no more than one previous
chemotherapy regimen, had Eastern Cooperative Oncology
Group performance status 2, an ANC 1.5  109/L, platelet
count 100  109/L, and adequate hepatic, cardiac, and renal
function for the chosen chemotherapy-regimen.
METHODS
This was a multinational, multicenter, randomized,
controlled phase-III study. A total of 240 patients were
randomized to treatment with either XM02 (n  160) or
Filgrastim (n  80) in the first chemotherapy cycle. In the
subsequent cycles, all patients received XM02. The patients
underwent a maximum of 6 chemotherapy cycles (3 or 4
weeks per cycle, depending on the chemotherapy protocol),
each cycle beginning with a chemotherapy infusion on Day 1.
In each cycle, 24 hours after the last chemotherapy infusion,
the patients received daily s.c. injections of 5 g/kg/d (based
on actual body weight) XM02 or Filgrastim (Filgrastim in the
first cycle only) for at least 5 days and a maximum of 14 days
according to the Summary of Product Characteristics of
Neupogen.4 If a chemotherapy protocol required chemother-
apy infusions during the cycle, simultaneous administration
of study drug on these days was at the discretion of the
investigator. Study drug had to be stopped when an ANC of
10  109/L after nadir was reached. Blood samples for the
determination of the ANC were taken within 24 hours before
chemotherapy and then daily starting on Day 2 (in cycles 2–6
starting on Day 5) until Day 15, or longer until ANC reached
2.0  109/L. Body temperature (axillary) was measured
with a standardized device daily until Day 15, or longer until
ANC reached 2.0  109/L.
Endpoints and Definitions
Efficacy endpoints included the duration of severe
neutropenia (DSN) in cycles 1 and 4, defined as the number
of days with grade 4 neutropenia with an ANC0.5 109/L,
the incidence of observed febrile neutropenia (FN) (observed
FN defined as body temperature of 38.5°C for more than 1
hour and ANC 0.5  109/L, both measured on the same
day) and of protocol defined FN (intake of systemic antibi-
otics) by cycle and across all cycles, the depth of ANC nadir
in cycles 1 and 4, and the time to ANC recovery in cycles 1
and 4. Safety assessment was based on adverse events (AEs),
laboratory parameters, physical examinations, and vital signs.
Statistical Methods
All safety analyses were summarized using descriptive
statistics. In addition, the incidence of AEs was compared for
XM02 versus Filgrastim using Fisher exact test (two-sided
p-values). The Wilcoxon test was used to compare changes of
safety laboratory parameters from baseline between the two
active groups.
Analysis of covariance was applied for DSN, ANC
nadir, and time to ANC recovery. All analyses of efficacy
endpoints were done without alpha-adjustment and were
interpreted as descriptive/exploratory analyses. Incidences of
FN were compared between XM02 and Filgrastim by means
of the Cochran-Mantel-Haenszel test.
The primary objective of the study was to demonstrate
safety of XM02 in patients with lung cancer. The sample size
of 240 patients appeared to be sufficient to meet this objective
and was not determined by means of statistical sample size
calculations. Nevertheless, with 240 patients the probability
of observing at least one case of a specific AE, which has a
true incidence rate of 0.5% was approximately 70%, and it
was approximately 91% if the true incidence rate is 1%.
RESULTS
Of the 240 randomized patients, 219 patients (91.3%)
completed cycle 1 and 115 patients (47.9%) prematurely
terminated the study, 41 (17.1%) because of progression of
underlying disease, 21 (8.8%) withdrew consent, 20 (8.3%)
due to AEs, 12 (5.0%) because of death, and 6 (2.5%) due to
noncompliance; 15 patients (6.3%) prematurely terminated
the study due to other reasons. Overall, the patients were
exposed to study drug for a median of 49.0 days (range,
2.0–84.0 days). Median duration within the cycles was 10.0
to 11.5 days (range, 2–15 days). The majority of patients
(48.8%) received a chemotherapy combination of cisplatin 
etoposide. Other frequently applied chemotherapy combina-
tions were cisplatin  gemcitabine (15.3%), carboplatin 
vinorelbine (8.3%), carboplatin  etoposide (7.4%), carbo-
platin  gemcitabine (6.2%), carboplatin  paclitaxel
(6.2%), and cisplatin  vinorelbine (5.4%). The treatment
groups were similar with regard to disposition, and study
drug and chemotherapy exposure. Demographic, baseline,
and disease characteristics are summarized in Table 1.
Efficacy
Results are summarized in Table 2 for the full analysis set.
Duration of Severe Neutropenia
In the full analysis set, mean DSN was 0.5 and 0.3 days
in cycle 1 for XM02 and Filgrastim, respectively, and 0.4 and
0.3 days in cycle 4 after the switch from Filgrastim to XM02
in the reference group. In the analysis of covariance for DSN
in cycle 1, the estimated treatment difference “XM02 minus
Filgrastim” was 0.157 days, with 95% confidence interval
(0.114 days, 0.428 days), which was included in the pre-
specified equivalence range (1, 1).
Febrile Neutropenia
In cycle 1, incidences of observed or protocol defined
FN were 15.0% for XM02 and 8.8% for Filgrastim (p 
0.2347), and in cycle 4, after switch from Filgrastim to XM02
in the reference group, incidences were 4.3% and 3.3% (p 
0.9036), respectively. Across all cycles, the incidence of
observed or protocol defined FN was 33.1% and 23.8% in the
XM02 and Filgrastim/XM02 groups, respectively.
Absolute Neutrophil Count
In cycle 1 in both treatment groups, mean ANC values
increased after Day 2, reaching a maximum on Day 5 and
then decreased to a nadir on Day 11 (Day 12 for Filgrastim
group). Thereafter, mean values increased again, reaching a
maximum on Day 14. On Day 21, mean values approached
those observed on Day 1 in both treatment groups. The ANC
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profile was similar in cycles 2 to 6. The ANC profile of
patients receiving chemotherapy of myelotoxic potency cat-
egory “platinum/etoposide” (mean DSN under this treatment
regimen was 0.5 days) is shown in Figure 1.
In cycle 1, mean ANC nadir values were 2.1 109/L in
the XM02 group and 2.9  109/L in the Filgrastim group. In
cycle 4, after switch from Filgrastim to XM02 in the refer-
ence group, mean ANC nadir values were 2.3  109/L and
3.2  109/L in the XM02 and Filgrastim/XM02 groups,
respectively.
In cycle 1, mean time to ANC recovery was 6.3 days in
the XM02 group and 4.5 days in the Filgrastim group. In
cycle 4, after switch from Filgrastim to XM02 in the refer-
ence group, mean time to ANC recovery was 6.4 days and 4.5
days in the XM02 and Filgrastim/XM02 groups, respectively.
Adverse Events
In the course of the study, 223 patients (94.1%) expe-
rienced a total of 2215 treatment emergent AEs (TEAEs). Of
these, 203 were considered as severe in 95 patients (40.1%).
There were 112 serious AEs (SAEs) in 72 patients (30.4%),
and 31 patients (13.1%) discontinued the study due to a
TEAE. There were 22 patients with TEAEs with outcome
death (9.3%) during the study observation period, i.e., until
30 days after end of study. All deaths were considered not to
be related to the study drug. One patient died on Day 17 in
cycle 1 from an afebrile sepsis, 13 days after start of treatment
with XM02. The patient had received a 3-day chemotherapy
regimen with cisplatin and etoposide. The patient developed
severe neutropenia on Day 10 with a nadir ANC value of
0.2  109/L on Day 11. On Day 15, 1 day before the patient
developed first symptoms (disorientation and weakness), the
patient’s ANC was 13.5 109/L, and the last measured value
on Day 17 was 32.3  109/L. The patient had no clinical
signs of sepsis, in particular no fever.
Overall, commonly reported TEAEs were nausea (in
49.8% of patients), anemia (38.8%), and vomiting (35.9%).
Most often reported drug-related AEs were anemia (2.1%),
myalgia (2.1%), back pain (2.1%), and headache (2.1%). In
general, drug-related AEs occurred early in the study, i.e.,
they were reported within 20 days after study start, or within
6 days after start of a cycle. Possibly drug-related AEs in
cycle 1 are displayed in Table 3. The AE profile was similar
between the XM02 and Filgrastim/XM02 groups.
No distinct changes were observed in the course of the
study for laboratory parameters, physical examination find-
ings, or vital signs, and there were no clinically relevant
differences between the treatment groups with regard to these
variables.
DISCUSSION
The primary aim of this study was to demonstrate
safety and efficacy of XM02 when administered for up to a
maximum of six chemotherapy cycles in patients with lung
cancer. A total of 237 patients in a heterogeneous patient
TABLE 1. Patient Characteristics—Safety Set
XM02
(n  158)
Neupogena
(n  79)
Gender (N %)
Male 127 (80.4%) 61 (77.2%)
Female 31 (19.6%) 18 (22.8%)
Age (yr)
Mean 58.8 58.1
SD 8.8 10.1
Median 58.5 59.0
Range 34–78 34–78
Race (N %)
Caucasian 149 (94.3%) 76 (96.2%)
Hispanic 8 (5.1%) 3 (3.8%)
Other 1 (0.6%) 0 (0.0%)
Body mass index (kg/m²)
Mean 23.99 24.41
SD 4.22 4.17
Median 23.50 24.20
Range 16.0–39.6 16.4–36.4
Cancer type (N %)
Small cell 26 (16.5%) 13 (16.5%)
Non-small cell 132 (83.5%) 66 (83.5%)
Cancer stage (N %)
Limited (small cell) 6 (3.8%) 2 (2.5%)
Extensive (small cell) 20 (12.7%) 11 (13.9%)
Stage 3 (non small cell) 54 (34.2%) 22 (27.8%)
Stage 4 (non small cell) 78 (49.4%) 44 (55.7%)
Prior therapy (N %)
Chemotherapy (yes) 21 (13.3%) 12 (15.2%)
Radiation therapy (yes) 20 (12.7%) 7 (8.9%)
ECOG before cycle 1 (N %)
Status 0 29 (18.4%) 19 (24.1%)
Status 1 100 (63.3%) 43 (54.4%)
Status 2 29 (18.4%) 17 (21.5%)
Body mass index calculated as body weight/(height)².
a Patients in this group received Neupogen in cycle 1 and XM02 afterward.
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Results of Efficacy Endpoints
Treatment Group XM02 Neupogena
Full Analysis Set (n) (n  160) (n  80)
Mean DSN (days)
Cycle 1 0.5 0.3
Cycle 4 0.4 0.3
Mean ANC nadir (109/L)
Cycle 1 2.1 2.9
Cycle 4 2.3 3.2
Mean time to ANC recovery (days)
Cycle 1 6.3 4.5
Cycle 4 6.4 4.5
Incidence of FN (%)b
Cycle 1 15.0 8.8
Across all cycles 33.1 23.8
a Patients in this group received Neupogen in cycle 1 and XM02 afterward
(including in cycle 4).
b Observed or protocol defined FN.
DSN, duration of severe neutropenia; ANC, absolute neutrophil count; FN, febrile
neutropenia.
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population were exposed to XM02 in the course of the study.
XM02 demonstrated similar efficacy and safety profile as the
reference medication Filgrastim.
The most often reported drug-related TEAEs in this
study were myalgia, back pain, anemia, and headache.
Bone and muscle pain are known adverse drug reactions to
G-CSFs, however, occurring with a higher incidence than
seen in this study.
Of the observed deaths, none were related to study drug
but primarily to progression/refractoriness of underlying dis-
ease and—to a smaller extent—to AEs of applied chemother-
apy. These data reflect the clinical course of patients with
advanced non-small cell lung cancer and an overall rather
dismal prognosis. The overall mortality observed (9.3%) in
this study was in the expected range.5,6 One patient died of an
afebrile sepsis, no other patients died of FN or infections.
The incidence of observed or protocol defined FN in
cycle 1 was 15.0% and 8.8% in the XM02 and Filgrastim
groups, respectively. In a study conducted by Timmer-Bonte
et al.,7 the incidence of FN in cycle 1 of lung cancer
chemotherapy was 10% in patients treated with antibiotics 
G-CSF.
In a study in 348 breast cancer patients published by del
Giglio et al.8 comparing XM02 and Filgrastim versus placebo
in cycle 1 in a homogenous population receiving docetaxel 75
mg/m2/doxorubicin 60 mg/m2 chemotherapy equivalence of
XM02 versus Filgrastim and superiority versus placebo was
clearly demonstrated with a DSN in cycle 1 of 1.1, 1.1, and
3.8 days in the XM02, Filgrastim, and placebo group, respec-
tively. In the same study, the incidence of FN in cycle 1 was
12.1, 12.5, and 38.1% under XM02, Filgrastim, and placebo,
respectively. Another study in the same development pro-
gram was conducted by Engert et al.9 in 92 non-Hodgkin-
lymphoma patients comparing XM02 and Filgrastim in the
first cycle of cyclophosphamide-hydroxydaunomycin-oncovin-
prednisolon or rituximab cyclophosphamide-hydroxydaunomy-
cin-oncovin-prednisolon chemotherapy. In this study, there was
a trend to better efficacy results in the XM02 group compared
FIGURE 1. Mean (	SD) of abso-
lute neutrophil counts in cycle 1.
Full analysis (FA) set—patients re-
ceiving chemotherapy of myelotoxic
potency category etoposide.
TABLE 3. Possibly Drug Related Adverse Events Cycle 1
Treatment Group XM02 Filgrastim
Safety Set (n) (n  158) (n  79)
System Organ Class Preferred Term N % E N % E
Musculoskeletal and connective tissue disorders 7 4.4 7 3 3.8 3
Back pain 2 1.3 2 2 2.5 2
Myalgia 2 1.3 2 1 1.3 1
Bone pain 2 1.3 2 0 0.0 0
Musculoskeletal pain 1 0.6 1 0 0.0 0
General disorders and administration site
conditions
5 3.2 7 3 3.8 4
Pyrexia 3 1.9 3 1 1.3 2
Fatigue 1 0.6 1 1 1.3 1
Asthenia 1 0.6 2 0 0.0 0
Chest pain 1 0.6 1 0 0.0 0
Injection site pain 0 0.0 0 1 1.3 1
Gastrointestinal disorders 4 2.5 4 0 0.0 0
Abdominal pain 1 0.6 1 0 0.0 0
Gastrointestinal disorder 1 0.6 1 0 0.0 0
Nausea 1 0.6 1 0 0.0 0
Vomiting 1 0.6 1 0 0.0 0
Nervous system disorders 3 1.9 3 1 1.3 1
Headache 3 1.9 3 1 1.3 1
Skin and subcutaneous tissue disorders 1 0.6 1 2 2.5 3
Rash 0 0.0 0 1 1.3 2
Eczema 1 0.6 1 0 0.0 0
Rash pruritic 0 0.0 0 1 1.3 1
Investigations 2 1.3 2 1 1.3 1
Body temperature increased 1 0.6 1 1 1.3 1
Aspartate aminotransferase increased 1 0.6 1 0 0.0 0
Blood and lymphatic system disorders 2 1.3 2 0 0.0 0
Thrombocythaemia 1 0.6 1 0 0.0 0
Thrombocytopenia 1 0.6 1 0 0.0 0
Metabolism and nutrition disorders 1 0.6 1 0 0.0 0
Hyponatraemia 1 0.6 1 0 0.0 0
Vascular disorders 1 0.6 1 0 0.0 0
Thrombophlebitis 1 0.6 1 0 0.0 0
N  number of patients exposed to study drug or number of patients affected by TEAEs.
%  100  (N affected/N exposed).
E number of events for the N patients. Adverse events were coded using MedDRA 7.1.
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with the Filgrastim group with a DSN of 0.5 days (XM02) and
0.9 days (Filgrastim) and an incidence of FN of 11.1% (XM02)
and 20.7% (Filgrastim) in cycle 1.
These inconsistent results on the incidence of FN in the
three studies in breast cancer, lung cancer, and non-Hodgkin-
lymphoma representing the complete XM02 development
program in cancer patients will be further investigated in a
meta-analysis on the incidence of FN in cycle 1 (manuscript
in preparation).
For patients receiving XM02 or Filgrastim, the ANC
values distinctly increased after start of treatment, reaching a
maximum on Day 5, and then decreased to a nadir around
Day 11. Thereafter, ANC values increased again, reaching a
maximum on Day 14. On Day 21, mean values returned to
values as observed on Day 1. Holmes et al.1 reported the same
biphasic ANC profile under treatment with Filgrastim.
The benefit of the biosimilar G-CSF XM02 may be
improved cost-effectiveness associated with a similar safety
and efficacy profile compared with the reference product.
In conclusion, treatment with XM02 is beneficial in
ameliorating severe neutropenia and FN in lung cancer pa-
tients receiving myelosuppressive chemotherapy. XM02 is
safe and well tolerated in the doses applied in this study.
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